Pontus K.E. Börjesson

Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients

Pontus K.E. Börjesson, Yvonne W. S. Jauw, Ronald Boellaard et al. · Clinical Cancer Research · 2006 · 234 citations · Full text

Radiation Dosimetry of ⁸⁹Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients

Pontus K.E. Börjesson, Yvonne W. S. Jauw, Remco de Bree et al. · Journal of Nuclear Medicine · 2009 · 168 citations · Full text

Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

Pontus K.E. Börjesson, Ernst J. Postema, Jan C. Roos et al. · PubMed · 2003 · 114 citations

Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.

Ernst J. Postema, Pontus K.E. Börjesson, W C Buijs et al. · PubMed · 2003 · 42 citations

Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.

David R. Colnot, Gert J. Ossenkoppele, Jan C. Roos et al. · PubMed · 2002 · 29 citations